#IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

1 week ago

Hansa Biopharma's Imlifidase BLA Receives PDUFA Date for December 2026 Hansa Biopharma's Imlifidase BLA is set for PDUFA review by the FDA on December 19, 2026, marking a significant step for kidney transplant patients.

Hansa Biopharma's Imlifidase BLA Receives PDUFA Date for December 2026 #Sweden #Lund #Hansa_Biopharma #imlifidase #IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

1 month ago

Hansa Biopharma Reports Impressive Financial Performance for Q4 and Full Year 2025 Hansa Biopharma AB announced strong financial results for both Q4 2025 and the entire year. With revenue growth and successful product milestones, the company looks ahead to future developments in kidney transplantation.

Hansa Biopharma Reports Impressive Financial Performance for Q4 and Full Year 2025 #Sweden #FDA_Approval #Lund #Hansa_Biopharma #IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

7 months ago

Hansa Biopharma Achieves Strong Financial Growth and Pipeline Progress in Q2 2025 Hansa Biopharma's Q2 2025 results reflect significant sales growth and strategic financing, focusing on critical Phase 3 trials in transplantation.

Hansa Biopharma Achieves Strong Financial Growth and Pipeline Progress in Q2 2025 #Sweden #financial_results #Lund #Hansa_Biopharma #IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

7 months ago

Hansa Biopharma Reports Significant Financial Progress in Q2 2025 Hansa Biopharma has shared its impressive interim financial results for the first half of 2025, reflecting strong sales growth and strategic advancements in their pipeline.

Hansa Biopharma Reports Significant Financial Progress in Q2 2025 #Sweden #Lund #Hansa_Biopharma #IDEFIRIX #Phase_3_Trials

Thiard News@F4F

@newsen.bsky.social

10 months ago

Hansa Biopharma Welcomes Maria Törnsén as New COO and U.S. President Hansa Biopharma has appointed Maria Törnsén as the new Chief Operating Officer and President for the U.S., effective May 19, 2025.

Hansa Biopharma Welcomes Maria Törnsén as New COO and U.S. President #Sweden #Lund #Hansa_Biopharma #IDEFIRIX #Maria_Törnsén

Thiard News@F4F

@newsen.bsky.social

10 months ago

Maria Törnsén Takes the Helm as COO and President of Hansa Biopharma in the U.S. Maria Törnsén has been appointed COO and President U.S. at Hansa Biopharma, bringing over 20 years of experience in the biotech field. Her leadership aims to drive growth and innovation.

Maria Törnsén Takes the Helm as COO and President of Hansa Biopharma in the U.S. #USA #Lund #Hansa_Biopharma #IDEFIRIX #Maria_Törnsén

Thiard News@F4F

@newsen.bsky.social

10 months ago

Hansa Biopharma Announces Impressive First Quarter Financial Results for 2025 In its first quarter report for 2025, Hansa Biopharma showcases significant revenue growth, product sales increases, and promising pipeline advancements.

Hansa Biopharma Announces Impressive First Quarter Financial Results for 2025 #Sweden #financial_results #Lund #Hansa_Biopharma #IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

10 months ago

Hansa Biopharma Releases Strong Financial Results for Q1 2025, Highlighting Growth and Innovations Hansa Biopharma has announced its impressive financial results for Q1 2025, showing significant growth in product sales and notable pipeline advancements.

Hansa Biopharma Releases Strong Financial Results for Q1 2025, Highlighting Growth and Innovations #Sweden #Lund #Hansa_Biopharma #IDEFIRIX #HNSA-5487

Thiard News@F4F

@newsen.bsky.social

11 months ago

Hansa Biopharma Unveils 2024 Annual and Sustainability Reports, Showcasing Growth and Commitment Hansa Biopharma has released its Annual and Sustainability Reports for 2024, highlighting significant sales growth, innovative therapies, and a commitment to sustainability in healthcare.

Hansa Biopharma Unveils 2024 Annual and Sustainability Reports, Showcasing Growth and Commitment #Sustainability #Sweden #Lund #Hansa_Biopharma #IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

11 months ago

Hansa Biopharma Unveils Its Annual and Sustainability Reports for 2024 Hansa Biopharma has released its 2024 Annual and Sustainability Reports, showcasing significant advancements in innovative treatments and sustainable practices.

Hansa Biopharma Unveils Its Annual and Sustainability Reports for 2024 #Sweden #Lund #Hansa_Biopharma #IDEFIRIX #HNSA-5487

Thiard News@F4F

@newsen.bsky.social

1 year ago

Hansa Biopharma Closes Enrollment for Pivotal Phase 3 Study in Kidney Transplant Patients Hansa Biopharma has completed enrollment in a Phase 3 study aimed at improving kidney transplant outcomes for highly sensitized patients, utilizing their innovative treatment IDEFIRIX.

Hansa Biopharma Closes Enrollment for Pivotal Phase 3 Study in Kidney Transplant Patients #Sweden #Lund #kidney_transplant #Hansa_Biopharma #IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

1 year ago

Hansa Biopharma Concludes Enrollment in Pivotal Phase 3 Study for Highly Sensitized Kidney Transplant Patients Hansa Biopharma has successfully finished enrolment in a crucial Phase 3 study aimed at enhancing kidney transplant outcomes for highly sensitized patients. This key research could influence future transplant protocols.

Hansa Biopharma Concludes Enrollment in Pivotal Phase 3 Study for Highly Sensitized Kidney Transplant Patients #Sweden #Lund #kidney_transplant #Hansa_Biopharma #IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

1 year ago

Hansa Biopharma's 2024 Financials Reveal Major Growth in IDEFIRIX Sales and Pipeline Advances Hansa Biopharma's financial results for 2024 highlight significant growth in IDEFIRIX sales and notable progress in their drug development pipeline, pointing towards a solid future.

Hansa Biopharma's 2024 Financials Reveal Major Growth in IDEFIRIX Sales and Pipeline Advances #Sweden #financial_results #Lund #Hansa_Biopharma #IDEFIRIX

Thiard News@F4F

@newsen.bsky.social

1 year ago

Hansa Biopharma Achieves Record Growth in 2024 Financial Results Driven by IDEFIRIX Success Hansa Biopharma reports transformative financial results for 2024, with significant growth in IDEFIRIX sales and progress in clinical trials.

Hansa Biopharma Achieves Record Growth in 2024 Financial Results Driven by IDEFIRIX Success #Sweden #Lund #Hansa_Biopharma #financial_report #IDEFIRIX